Abstract: This invention provides a DNA comprising any of the following (a) to (c): (a) a DNA comprising any of the base sequences of positions 16 to 831 of SEQ ID NO: 1, positions 16 to 822 of SEQ ID NO: 3, positions 16 to 825 of SEQ ID NO: 5, positions 16 to 819 of SEQ ID NO: 7, positions 16 to 834 of SEQ ID NO: 9, and positions 16 to 828 of SEQ ID NO: 11; (b) a DNA encoding a polypeptide comprising any of the amino acid sequences of positions 1 to 272 of SEQ ID NO: 2, positions 1 to 269 of SEQ ID NO: 4, positions 1 to 270 of SEQ ID NO: 6, positions 1 to 268 of SEQ ID NO: 8, positions 1 to 273 of SEQ ID NO: 10, and positions 1 to 271 of SEQ ID NO: 12; and (c) a complementary strand of the DNA (a) or (b).

Abstract: The object of the present invention is to provide an easy and quick detection method for detecting an oxLDL/?2GPI complex in biological samples, and a detection kit therefor. The present invention attains this object by providing a detection method for detecting an oxLDL/?2GPI complex, which uses a test strip for lateral flow assay, comprising a step of capturing the oxLDL/?2GPI complex in the test sample in a predetermined position on the test strip by a first binding component that binds to the oxLDL/?2GPI complex; and a step of labeling the oxLDL/?2GPI complex captured in the predetermined position on the test strip by making a second binding component comprising a labeling agent be bound to the captured oxLDL/?2GPI complex, and a detection kit therefor.

Abstract: This invention provides a DNA comprising any of the following (a) to (c): (a) a DNA comprising any of the base sequences of positions 16 to 831 of SEQ ID NO: 1, positions 16 to 822 of SEQ ID NO: 3, positions 16 to 825 of SEQ ID NO: 5, positions 16 to 819 of SEQ ID NO: 7, positions 16 to 834 of SEQ ID NO: 9, and positions 16 to 828 of SEQ ID NO: 11; (b) a DNA encoding a polypeptide comprising any of the amino acid sequences of positions 1 to 272 of SEQ ID NO: 2, positions 1 to 269 of SEQ ID NO: 4, positions 1 to 270 of SEQ ID NO: 6, positions 1 to 268 of SEQ ID NO: 8, positions 1 to 273 of SEQ ID NO: 10, and positions 1 to 271 of SEQ ID NO: 12; and (c) a complementary strand of the DNA (a) or (b).

Abstract: From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, and analyzed their specificities. The result showed that fluorescently labeled anti-oxidized LDL/?2GPI complex antibodies that are specific to a particular epitope were effective for imaging.

Abstract: The present inventors carried out immunization using renal/urinary calculus-derived calcified globules or carotid artery-derived arteriosclerotic plaques, and then obtained antibodies specific to calcified globules (NLO) via screening with NLO. The present inventors demonstrated that the antibodies reacted specifically to arteriosclerotic lesions (calcified lesions) and visualized arteriosclerotic plaques (in particular, calcified lesions) by using fluorescently labeled antibodies. Accordingly, the present inventors completed the present invention.

Abstract: From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, and analyzed their specificities. The result showed that fluorescently labeled anti-oxidized LDL/?2GPI complex antibodies that are specific to a particular epitope were effective for imaging.

Abstract: The present inventors carried out immunization using renal/urinary calculus-derived calcified globules or carotid artery-derived arteriosclerotic plaques, and then obtained antibodies specific to calcified globules (NLO) via screening with NLO. The present inventors demonstrated that the antibodies reacted specifically to arteriosclerotic lesions (calcified lesions) and visualized arteriosclerotic plaques (in particular, calcified lesions) by using fluorescently labeled antibodies. Accordingly, the present inventors completed the present invention.

Abstract: Serum amyloid P component, oxidized LDL and ?2-glycoprotein I can together form a complex. The presence of a disease such as hyperlipemia and atherosclerosis can be determined by detecting the complex by using either one of an anti-serum amyloid P component antibody and an anti-?2-glycoprotein I antibody.

Abstract: A complex having oxLDL bound covalently to ?2-GPI can be used as a standard for measuring a ?2-GPI/oxLDL complex in the living body thereby measuring the ?2-GPI/oxLDL complex in the living body more accurately and strictly, and can be utilized to provide a new measurement method, detection method, kit etc.

Abstract: The present invention provides a method for measuring a “complex of oxidized LDL and CRP” which comprises using an “anti-CRP antibody”. An “anti-apoB antibody and/or anti-?2-GPI antibody” is preferably used in the method of the present invention, which preferably comprises at least a step for forming a sandwich complex represented by “the anti-apoB antibody and/or anti-?2-GPI antibody”-“the complex of oxidized LDL and CRP”-“the anti-CRP antibody”. Either the “anti-apoB antibody and/or anti-?2-GPI antibody” or the “anti-CRP antibody” is preferably immobilized on a solid phase. According to the measuring method of the present invention, the “complex of oxidized LDL and CRP” may be simply, promptly and easily measured with high sensitivity, high accuracy at a lower cost.

Abstract: The cholesterol derivative, represented by the following formula (1): wherein R represents a C3–C23 saturated or unsaturated aliphatic hydrocarbon residue having an optional substituent, and, to the cholesterol backbone, —OH, —CHO, —COOH, —OOH, or an epoxy group may be added, specifically binds to ?2-glycoprotein. By use of the derivative, ?2-glycoprotein or a similar substance can be assayed in a very practical manner. Through the assay, a disease can be detected in a very practical manner.

Abstract: The present invention provides a method for measuring a “complex of oxidized LDL and CRP” which comprises using an “anti-CPR antibody”. An “anti-apoB antibody and/or anti-?2-GPI antibody” is preferably used in the method of the present invention, which preferably comprises at least a step for forming a sandwich complex represented by “the anti-apoB antibody and/or anti-?2-GPI antibody”—“the complex of oxidized LDL and CRP”—“the anti-CPR antibody”. Either the “anti-apoB antibody and/or anti-?2-GPI antibody” or the “anti-CRP antibody” is preferably immobilized on a solid phase. According to the measuring method of the present invention, the “complex of oxidized LDL and CRP” may be simply, promptly and easily measured with high sensitivity, high accuracy at a lower cost.

Abstract: A complex having oxLDL bound covalently to ?2-GPI can be used as a standard for measuring a ?2-GPI/oxLDL complex in the living body thereby measuring the ?2-GPI/oxLDL complex in the living body more accurately and strictly, and can be utilized to provide a new measurement method, detection method, kit etc.

Abstract: By allowing serum or plasma samples collected from humans to react with laminin-1 or a fragment thereof, and then determining whether or not anti-laminin-1 antibody, an auto-antibody against laminin-1, in the sample bound to laminin-1 to detect anti-laminin-1 antibody in the sample, gynecology-related diseases such as habitual abortion, sterility, infertility, and endometriosis can be diagnosed.

Abstract: The cholesterol derivative, represented by the following formula (1): 1

Abstract: By allowing serum or plasma samples collected from humans to react with laminin-1 or a fragment thereof, and then determining whether or not anti-laminin-1 antibody, an auto-antibody against laminin-1, in the sample bound to laminin-1 to detect anti-laminin-1 antibody in the sample, gynecology-related diseases such as habitual abortion, sterility, infertility, and endometriosis can be diagnosed.

Abstract: In a method for assaying an anticardiolipin antibody in a sample utilizing .beta.2-glycoprotein I, a polypeptide having the same amino acid sequence as domain IV of .beta.2-glycoprotein I or a polypeptide partially different therefrom but functionally equivalent thereto is used in place of .beta.2-glycoprotein I itself. According to this method, an autoantibody from patients with antiphospholipid syndrome can be accurately assayed in a simple manner.

Abstract: Use of an anti-cardiolipin antibody, anti-lipoprotein antibody or anti-.beta.2-glycoprotein I antibody together with an immobilized antibody thereof enables to accurately assay for a complex of .beta.2-glycoprotein I and an oxidized lipoprotein in a blood sample, according to a sandwich immunoassay. Thus, the oxidized lipoprotein in blood can be detected, whereby diagnosis of arteriosclerotic disease is enabled.

Abstract: A monoclonal antibody which is capable of specifically binding with human pulmonary surfactant apoprotein D has been successfully obtained. Using the monoclonal antibody, human pulmonary surfactant apoprotein D can be specifically detected and assayed, whereby diagnosis of respiratory diseases is enabled.

Abstract: As a carrier for binding of the antiphospholipid antibodies used for immunological diagnosis of antiphospholipid syndrome, a phospholipid-bound carrier treated with purified serum albumin and a surfactant is used. Thus, immunological diagnosis of antiphospholipid syndrome can be made with high accuracy. By using the fraction or protein obtained from animal serum or plasma, having the activity of enhancing the binding ability of the antibodies specifically present in the antiphospholipid syndrome to the phospholipid, immunological diagnosis of antiphospholipid syndrome can also be made more accurately, as compared to known diagnosis.